Search Results

LOTEVIB T EYE DROP

LOTEPREDNOL ETABONATE 0.5%w/v IP + TOBRAMYCIN SULPHATE 0.3%w/v IP + BENZALKONIUM...

Send Enquiry

OPTHO

Drops

Packaging and packing Type

| 5ml

MRP :

₹196

PTR :

₹140

PTS :

₹126

A topical ophthalmic combination [corticosteroid/antibiotic] for the management of various ocular surface inflammatory conditions with, or at risk for... Read More

Composition

LOTEPREDNOL ETABONATE 0.5%w/v IP + TOBRAMYCIN SULPHATE 0.3%w/v IP + BENZALKONIUM CHLORIDE 0.004%v/v IP

Send Enquiry

India’s Largest Pharma Franchise

100%

Genuine Products

Secure

Payments

24 x 7

Customer Support

About the product

Description

A topical ophthalmic combination [corticosteroid/antibiotic] for the management of various ocular surface inflammatory conditions with, or at risk for, a bacterial infection. (James E Deom, 2022) An effective ophthalmic suspension for the treatment of ocular inflammation associated with blepharokeratoconjunctivitis. (Eric M White, 2008) A viable combination therapy that increases convenience that promotes patient adherence. (Karpecki, 2021) Demonstrates high rates of bacterial eradication in patients with bacterial conjunctivitis (94.3–98.5%) and blepharoconjunctivitis (88.9%). (Karpecki, 2021) A well-tolerated agent in pediatric populations 0 to 6 years of age with blepharitis or blepharoconjunctivitis. (Karpecki, 2021) A safer therapeutic option for ocular inflammation that carries a risk of superficial bacterial infections. (Timothy L Comstock E. J., 2010) Protects against infection after surgery as well as treats existing infections by eradicating susceptible organisms. (Karpecki, 2021) An efficacious drug in a range of inflammatory ocular conditions along with a safety profile including a low risk of intraocular pressure elevation. (James E Deom, 2022) Provides coverage against a broad spectrum of common ocular pathogens. (James E Deom, 2022) A suitable treatment option for blepharitis, including that caused by a staphylococcal infection. (Karpecki, 2021) An appropriate treatment for other ocular surface inflammatory conditions that carry a risk of infection, such as contact lens-induced red eye. (Karpecki, 2021) A potent therapeutic option that is effective in reducing the signs of blepharitis. (Timothy L Comstock, 2017) Demonstrates a favorable safety profile than dexamethasone 0.1%/tobramycin 0.3% ophthalmic suspensions in blepharitis subjects. (Timothy L Comstock, 2017)

Side Effects

Headache, Burning sensation in the eye, Swelling of your face, lips, tongue, or throat, Blurred vision, Increased intraocular pressure

Indication

Blepharokeratoconjunctivitis , Bacterial Conjunctivitis , Allergic Conjunctivitis , Uveitis , Keratitis , Blepharitis

Important Notice

Temp data

Storage Condition

Product details for storage condition Product details for storage condition Product details for storage condition Product details for storage condition

Similar Products

No products found.

Looking into the future of healthcare

Contact

Plot No 4, HSIIDC IT PARK, Sector 22,Panchkula, Haryana, India 134109

Phone: 9888988858

Business Hours

Mon-Sat: 9AM to 6PM

Franchise Enquiry

Request a callback to get more information about becoming a PCD Franchise Owner***

    Send Enquiry

    Request a callback to get more information about becoming a PCD Franchise Owner